Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to Dividend.com. Please help us personalize your experience.

Select the one that best describes you
Dividend logo

Gilead Sciences, Inc. (GILD ) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The company’s primary areas of focus are immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) and chronic hepatitis B virus (HBV), oncology and inflammation, and serious cardiovascular and respiratory conditions. The company has two high-profile treatments: Harvoni and Sovaldi. These two drugs accounted for nearly 60% of the company’s revenue in both quarters of 2015.

Additionally, Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands approximately 75% of the U.S. treatment market and more than 50% worldwide.

Gilead Sciences recently started paying a quarterly dividend of $0.43 per share. Its first payout was on 6/29/2015. It’s going Ex-Dividend again on 9/14/2015. Its annual payout comes to $1.72, yielding 1.50% on its current price of $114.

To read the Full Story, Go Premium or Log In

Popular Articles

Premium Turning%20knob%20fo%205g
News

A Big Dividend Boost from 5G

By historical standards, the various telecoms are pretty boring stocks to own.

Steady demand,...

News

AbbVie Inc: Banking on HUMIRA

AbbVie Inc (ABBV ) is a biopharmaceutical company that engages in the discovery, development,...

Premium Man%20spotting%20trouble%20through%20binoculars
News

The IMF Sees Trouble Ahead

Unless you’ve been living under a rock, it’s hard to ignore the growth in the global economy.

For...